Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Rigel Pharmaceuticals trading halted, news pending  13:04
12/01/22
12/01
13:04
12/01/22
13:04
RIGL

Rigel Pharmaceuticals

/

+

 
ShowHide Related Items >><<
RIGL Rigel Pharmaceuticals
/

+

RIGL Rigel Pharmaceuticals
/

+

08/18/22 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $15 from $7 at H.C. Wainwright
08/16/22 Piper Sandler
Rigel Pharmaceuticals price target raised to $2 from $1 at Piper Sandler
08/03/22 B. Riley
Rigel Pharmaceuticals price target raised to $1.75 from $1.25 at B. Riley
06/09/22 BMO Capital
Rigel Pharmaceuticals price target lowered to $3 from $7 at BMO Capital
RIGL Rigel Pharmaceuticals
/

+

RIGL Rigel Pharmaceuticals
/

+

Conference/Events
Oppenheimer emerging biotech analysts to hold analyst/industry conference call » 10:25
12/01/22
12/01
10:25
12/01/22
10:25
ACET

Adicet Bio

$18.31 /

+0.12 (+0.66%)

, ACLX

Arcellx

$20.08 /

+0.12 (+0.60%)

, ALLO

Allogene Therapeutics

$9.46 /

-0.38 (-3.86%)

, BMY

Bristol-Myers

$80.52 /

+0.33 (+0.41%)

, CELU

Celularity

$1.78 /

+0.08 (+4.71%)

, CLLS

Cellectis

$2.22 /

+0.01 (+0.45%)

, CRBU

Caribou Biosciences

$9.18 /

-0.145 (-1.55%)

, CRSP

Crispr Therapeutics

$54.83 /

+0.04 (+0.07%)

, DTIL

Precision BioSciences

$1.37 /

+0.01 (+0.74%)

, FATE

Fate Therapeutics

$20.93 /

+0.1 (+0.48%)

, GILD

Gilead

$88.72 /

+0.87 (+0.99%)

, GRCL

Gracell

$3.32 /

+0.07 (+2.15%)

, IPSC

Century Therapeutics

$10.45 /

-0.02 (-0.19%)

, JNJ

Johnson & Johnson

$178.00 /

+0.03 (+0.02%)

, LEGN

Legend Biotech

$51.29 /

-0.035 (-0.07%)

, MBIO

Mustang Bio

/

+

, NKTX

Nkarta

$8.43 /

-0.03 (-0.35%)

, PSTX

Poseida Therapeutics

$4.63 /

+0.09 (+1.98%)

Emerging Biotechnology…

Emerging Biotechnology Analysts Breidenbach and Biegler, along with Drs. Rossi and Braunstein, discuss the evolving treatment landscapes in multiple myeloma and non-hodgkin lymphoma on an Analyst/Industry conference call to be held on December 1 at 11 am.

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$4.63 /

+0.09 (+1.98%)

NKTX Nkarta
$8.43 /

-0.03 (-0.35%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$51.29 /

-0.035 (-0.07%)

JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

IPSC Century Therapeutics
$10.45 /

-0.02 (-0.19%)

GRCL Gracell
$3.32 /

+0.07 (+2.15%)

GILD Gilead
$88.72 /

+0.87 (+0.99%)

FATE Fate Therapeutics
$20.93 /

+0.1 (+0.48%)

DTIL Precision BioSciences
$1.37 /

+0.01 (+0.74%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

CRBU Caribou Biosciences
$9.18 /

-0.145 (-1.55%)

CLLS Cellectis
$2.22 /

+0.01 (+0.45%)

CELU Celularity
$1.78 /

+0.08 (+4.71%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

ALLO Allogene Therapeutics
$9.46 /

-0.38 (-3.86%)

ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

ACET Adicet Bio
$18.31 /

+0.12 (+0.66%)

ACET Adicet Bio
$18.31 /

+0.12 (+0.66%)

09/21/22 JPMorgan
Adicet Bio initiated with Overweight, $23 target at JPMorgan
09/21/22 JPMorgan
Adicet Bio initiated with an Overweight at JPMorgan
03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
03/17/22 JMP Securities
Adicet Bio price target lowered to $21 from $30 at JMP Securities
ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

10/31/22 Guggenheim
Arcellx initiated with a Buy at Guggenheim
10/27/22 Needham
Arcellx initiated with a Buy at Needham
07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
07/20/22 Canaccord
Arcellx initiated with a Buy at Canaccord
ALLO Allogene Therapeutics
$9.46 /

-0.38 (-3.86%)

11/21/22 H.C. Wainwright
Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
09/22/22 B. Riley
Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
09/20/22 B. Riley
B. Riley replaces Allogene with Syndax as top pick for 2022
08/10/22 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

11/17/22 Credit Suisse
Bristol-Myers initiated with a Neutral at Credit Suisse
11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
CELU Celularity
$1.78 /

+0.08 (+4.71%)

08/25/22 Alliance Global Partners
Celularity initiated with a Buy at Alliance Global Partners
08/23/22 Truist
Celularity price target lowered to $6 from $10 at Truist
06/22/22 H.C. Wainwright
Celularity initiated with a Buy at H.C. Wainwright
04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
CLLS Cellectis
$2.22 /

+0.01 (+0.45%)

08/18/22 Citi
Cellectis price target raised to $36 from $34 at Citi
05/18/22 Baird
Cellectis upgraded to Outperform at Baird on valuation 'backstop'
05/18/22 Baird
Cellectis upgraded to Outperform from Neutral at Baird
05/13/22 Barclays
Cellectis price target lowered to $7 from $9 at Barclays
CRBU Caribou Biosciences
$9.18 /

-0.145 (-1.55%)

11/23/22 Citi
Caribou Biosciences price target lowered to $37 from $38 at Citi
08/29/22 Citi
Caribou Biosciences price target lowered to $38 from $39 at Citi
08/18/22 H.C. Wainwright
Caribou Biosciences price target lowered to $27 from $28 at H.C. Wainwright
05/12/22 Citi
Caribou Biosciences price target raised to $39 from $29 at Citi
CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

11/23/22 Citi
Crispr Therapeutics price target lowered to $63 from $83 at Citi
11/02/22 Barclays
Crispr Therapeutics price target lowered to $61 from $88 at Barclays
11/02/22 Credit Suisse
Crispr Therapeutics price target lowered to $78 from $90 at Credit Suisse
10/11/22 Morgan Stanley
Crispr Therapeutics initiated with an Underweight at Morgan Stanley
DTIL Precision BioSciences
$1.37 /

+0.01 (+0.74%)

11/10/22 H.C. Wainwright
Precision BioSciences price target lowered to $17 from $20 at H.C. Wainwright
06/16/22 BMO Capital
Precision BioSciences initiated with an Outperform at BMO Capital
06/09/22 William Blair
Precision BioSciences downgraded to Market Perform at William Blair
12/13/21 BTIG
Precision BioSciences price target raised to $20 from $16 at BTIG
FATE Fate Therapeutics
$20.93 /

+0.1 (+0.48%)

11/16/22 Citi
Fate Therapeutics price target lowered to $80 from $87 at Citi
11/04/22 Cantor Fitzgerald
Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/10/22 Canaccord
Fate Therapeutics initiated with a Buy at Canaccord
08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
GILD Gilead
$88.72 /

+0.87 (+0.99%)

07:34 Today Oppenheimer
Gilead price target raised to $105 from $95 at Oppenheimer
11/22/22 Guggenheim
MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts
11/09/22 Argus
Gilead price target raised to $100 from $70 at Argus
11/08/22 Cowen
Gilead price target raised to $90 from $80 at Cowen
GRCL Gracell
$3.32 /

+0.07 (+2.15%)

09/22/22 Citi
Gracell initiated with a Buy at Citi
08/18/22 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
06/01/22 Cantor Fitzgerald
Gracell initiated with an Overweight at Cantor Fitzgerald
05/27/22 Piper Sandler
Gracell price target lowered to $10 from $25 at Piper Sandler
IPSC Century Therapeutics
$10.45 /

-0.02 (-0.19%)

11/14/22 H.C. Wainwright
Century Therapeutics price target lowered to $25 from $27 at H.C. Wainwright
11/11/22 Piper Sandler
Century Therapeutics price target raised to $24 at Piper after R&D day
10/31/22 Guggenheim
Century Therapeutics initiated with a Buy at Guggenheim
10/10/22 Canaccord
Century Therapeutics initiated with a Buy at Canaccord
JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

08:50 Today Jefferies
Horizon Therapeutics price target raised to $125 from $101 at Jefferies
08:42 Today Morgan Stanley
Johnson & Johnson price target raised to $178 from $170 at Morgan Stanley
11/30/22 Wells Fargo
Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
11/29/22 Craig-Hallum
Craig-Hallum sees potential for competing Apollo Endosurgery bids
LEGN Legend Biotech
$51.29 /

-0.035 (-0.07%)

11/01/22 Evercore ISI
Legend Biotech initiated with an Outperform at Evercore ISI
11/01/22 Cowen
Cowen starts Legend Biotech with an Outperform on Carvykti potential
11/01/22 Cowen
Legend Biotech initiated with an Outperform at Cowen
MBIO Mustang Bio
/

+

11/16/22 BTIG
Mustang Bio price target lowered to $4 from $8 at BTIG
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
07/14/22 B. Riley
Mustang Bio price target lowered to $4 from $5 at B. Riley
05/23/22 B. Riley
Mustang Bio price target lowered to $5 from $6 at B. Riley
NKTX Nkarta
$8.43 /

-0.03 (-0.35%)

11/16/22 Mizuho
Nkarta price target lowered to $26 from $81 at Mizuho
11/10/22 Oppenheimer
Nkarta price target lowered to $36 from $50 at Oppenheimer
10/10/22 Canaccord
Nkarta initiated with a Buy at Canaccord
08/12/22 Cantor Fitzgerald
Nkarta price target lowered to $38 from $60 at Cantor Fitzgerald
PSTX Poseida Therapeutics
$4.63 /

+0.09 (+1.98%)

11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
08/09/22 Piper Sandler
Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler
05/13/22 BTIG
Poseida Therapeutics price target lowered to $20 from $40 at BTIG
05/13/22 Piper Sandler
Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler
PSTX Poseida Therapeutics
$4.63 /

+0.09 (+1.98%)

NKTX Nkarta
$8.43 /

-0.03 (-0.35%)

MBIO Mustang Bio
/

+

JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

IPSC Century Therapeutics
$10.45 /

-0.02 (-0.19%)

GRCL Gracell
$3.32 /

+0.07 (+2.15%)

GILD Gilead
$88.72 /

+0.87 (+0.99%)

FATE Fate Therapeutics
$20.93 /

+0.1 (+0.48%)

DTIL Precision BioSciences
$1.37 /

+0.01 (+0.74%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

CRBU Caribou Biosciences
$9.18 /

-0.145 (-1.55%)

CLLS Cellectis
$2.22 /

+0.01 (+0.45%)

CELU Celularity
$1.78 /

+0.08 (+4.71%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

ALLO Allogene Therapeutics
$9.46 /

-0.38 (-3.86%)

ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

ACET Adicet Bio
$18.31 /

+0.12 (+0.66%)

  • 04
    Aug
  • 27
    Jul
  • 17
    Jun
  • 26
    Apr
  • 04
    Feb
  • 16
    Dec
  • 08
    Dec
JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

LEGN Legend Biotech
$51.29 /

-0.035 (-0.07%)

JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

GRCL Gracell
$3.32 /

+0.07 (+2.15%)

GILD Gilead
$88.72 /

+0.87 (+0.99%)

FATE Fate Therapeutics
$20.93 /

+0.1 (+0.48%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

CRBU Caribou Biosciences
$9.18 /

-0.145 (-1.55%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

ALLO Allogene Therapeutics
$9.46 /

-0.38 (-3.86%)

ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

ACET Adicet Bio
$18.31 /

+0.12 (+0.66%)

JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

IPSC Century Therapeutics
$10.45 /

-0.02 (-0.19%)

GILD Gilead
$88.72 /

+0.87 (+0.99%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

CELU Celularity
$1.78 /

+0.08 (+4.71%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

Hot Stocks
Sellas announces results from preclinical in vivo study of GFH009 » 08:35
12/01/22
12/01
08:35
12/01/22
08:35
SLS

Sellas Life Sciences

$2.39 /

+0.075 (+3.24%)

SELLAS Life Sciences…

SELLAS Life Sciences announced results from a preclinical in vivo study for its highly selective CDK9 inhibitor, GFH009, that demonstrate robust inhibition of tumor growth in a mouse xenograft model of small cell lung cancer, SCLC. GFH009 was tested against NCI-H209 SCL xenografts in athymic nude mice in four treatment groups of eight mice each consisting of GFH009 alone, olaparib alone, a combined regimen of GFH009 and olaparib, and a vehicle control. GFH009 treated mice exhibited a 40.4% decrease in mean tumor growth compared to the control group in this very aggressive cancer model which had a tenfold increase in average tumor volume over 20 days. Strongest effects were observed with GFH009 in combination with olaparib, with mean tumor growth decreased by 72.3%. Treatment with olaparib alone resulted in a 30.2% mean decrease in tumor growth. "We are looking forward to expanding use of GFH009 into solid cancers and these results indicate CDK9 can be an actionable target not only in the apoptotic pathway but also the DNA damage response pathway," said Dragan Cicic, MD, Senior Vice President, Clinical Development, of SELLAS. "This opens up additional avenues for the use of GFH009 in an expanding array of difficult to treat cancers based on their genomic and proteomic traits, moving another step towards truly personalized medicine."

ShowHide Related Items >><<
SLS Sellas Life Sciences
$2.39 /

+0.075 (+3.24%)

SLS Sellas Life Sciences
$2.39 /

+0.075 (+3.24%)

11/15/22 Alliance Global Partners
Sellas Life Sciences price target lowered to $8 from $14 at Alliance Global
06/28/22 Cantor Fitzgerald
Sellas Life Sciences price target lowered to $6 from $10 at Cantor Fitzgerald
04/07/22 Alliance Global Partners
Sellas Life Sciences price target lowered to $14 from $16.50 at Alliance Global Partners
12/03/21 Cantor Fitzgerald
Sellas Life Sciences price target lowered to $16 from $18 at Cantor Fitzgerald
  • 01
    Apr
SLS Sellas Life Sciences
$2.39 /

+0.075 (+3.24%)

Downgrade
OncoCyte downgraded to Hold from Buy at Lake Street » 08:35
12/01/22
12/01
08:35
12/01/22
08:35
OCX

OncoCyte

/

+

Lake Street analyst…

Lake Street analyst Thomas Flaten downgraded OncoCyte to Hold from Buy with a price target of 50c, down from $3, after the company announced the departure of Ronnie Andrews as CEO. The CEO's exit marks "the end of an eventful period in the company's history" and his lower rating reflects the incremental near-term uncertainty created by this change, Flaten tells investors.

ShowHide Related Items >><<
OCX OncoCyte
/

+

OCX OncoCyte
/

+

11/17/22 Piper Sandler
OncoCyte downgraded to Neutral at Piper with revenue ramp slowing
11/17/22 Piper Sandler
OncoCyte downgraded to Neutral from Overweight at Piper Sandler
11/14/22 Piper Sandler
OncoCyte price target lowered to $1 from $1.50 at Piper Sandler
08/17/22 Piper Sandler
OncoCyte price target raised to $1.50 from $1.40 at Piper Sandler
OCX OncoCyte
/

+

  • 14
    Apr
Hot Stocks
Nuvectis Pharma announces FDA granted FTD to NXP800 » 08:04
12/01/22
12/01
08:04
12/01/22
08:04
NVCT

Nuvectis Pharma

$7.17 /

+ (+0.00%)

Nuvectis Pharma announced…

Nuvectis Pharma announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to NXP800 for the treatment of platinum-resistant, ARID1A-mutated ovarian carcinoma. "We are very pleased with the FDA's decision to grant Fast Track Designation to NXP800 for the treatment of platinum-resistant, ARID1A-mutated ovarian carcinoma, which underscores the potential of NXP800 to address this serious condition of unmet medical need," said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis. Mr. Bentsur added, "We remain focused on our mission of developing novel treatments for severe oncological conditions, and we believe that with our pipeline of targeted-therapy drug candidates and experienced development team we are well positioned to achieve our goals."

ShowHide Related Items >><<
NVCT Nuvectis Pharma
$7.17 /

+ (+0.00%)

NVCT Nuvectis Pharma
$7.17 /

+ (+0.00%)

07/13/22 Ladenburg
Nuvectis Pharma initiated with a Buy at Ladenburg
05/10/22 H.C. Wainwright
Nuvectis Pharma price target raised to $21 from $14 at H.C. Wainwright
03/02/22 H.C. Wainwright
Nuvectis Pharma initiated with a Buy at H.C. Wainwright
NVCT Nuvectis Pharma
$7.17 /

+ (+0.00%)

  • 04
    Feb
Recommendations
Portage Biotech price target lowered to $21 from $22 at H.C. Wainwright » 06:09
12/01/22
12/01
06:09
12/01/22
06:09
PRTG

Portage Biotech

$5.75 /

-0.15 (-2.54%)

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PRTG Portage Biotech
$5.75 /

-0.15 (-2.54%)

PRTG Portage Biotech
$5.75 /

-0.15 (-2.54%)

11/30/22 Cantor Fitzgerald
Portage Biotech price target lowered to $18 from $26 at Cantor Fitzgerald
11/30/22 Oppenheimer
Portage Biotech price target lowered to $18 from $26 at Oppenheimer
09/20/22 H.C. Wainwright
Portage Biotech price target lowered to $22 from $32 at H.C. Wainwright
07/15/22 Oppenheimer
Portage Biotech assumed with an Outperform at Oppenheimer
PRTG Portage Biotech
$5.75 /

-0.15 (-2.54%)

PRTG Portage Biotech
$5.75 /

-0.15 (-2.54%)

PRTG Portage Biotech
$5.75 /

-0.15 (-2.54%)

Initiation
Fusion Pharmaceuticals resumed with a Buy at B. Riley » 05:56
12/01/22
12/01
05:56
12/01/22
05:56
FUSN

Fusion Pharmaceuticals

$2.25 /

+0.04 (+1.81%)

B. Riley analyst Yuan Zhi…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FUSN Fusion Pharmaceuticals
$2.25 /

+0.04 (+1.81%)

FUSN Fusion Pharmaceuticals
$2.25 /

+0.04 (+1.81%)

11/30/22 SVB Securities
Fusion Pharmaceuticals initiated with an Outperform at SVB Securities
09/15/22 Truist
Truist starts Fusion Pharmaceuticals at Buy with $10 price target
09/15/22 Truist
Fusion Pharmaceuticals initiated with a Buy at Truist
09/06/22 JonesTrading
Fusion Pharmaceuticals initiated with a Buy at JonesTrading
FUSN Fusion Pharmaceuticals
$2.25 /

+0.04 (+1.81%)

Conference/Events
Oppenheimer emerging biotech analysts to hold analyst/industry conference call » 04:55
12/01/22
12/01
04:55
12/01/22
04:55
ACET

Adicet Bio

$18.20 /

+0.42 (+2.36%)

, ACLX

Arcellx

$19.90 /

+ (+0.00%)

, ALLO

Allogene Therapeutics

$9.84 /

+0.56 (+6.03%)

, BMY

Bristol-Myers

$80.19 /

+1.18 (+1.49%)

, CELU

Celularity

$1.71 /

+0.035 (+2.10%)

, CLLS

Cellectis

$2.22 /

+0.04 (+1.83%)

, CRBU

Caribou Biosciences

$9.33 /

+0.985 (+11.81%)

, CRSP

Crispr Therapeutics

$54.69 /

+1.78 (+3.36%)

, DTIL

Precision BioSciences

$1.36 /

+0.06 (+4.62%)

, FATE

Fate Therapeutics

$20.84 /

+1.07 (+5.41%)

, GILD

Gilead

$87.85 /

+2.09 (+2.44%)

, GRCL

Gracell

$3.28 /

+0.04 (+1.23%)

, IPSC

Century Therapeutics

$10.48 /

+0.14 (+1.35%)

, JNJ

Johnson & Johnson

$177.94 /

+1.895 (+1.08%)

, LEGN

Legend Biotech

$51.25 /

+2.64 (+5.43%)

, MBIO

Mustang Bio

/

+

, NKTX

Nkarta

$8.46 /

+0.365 (+4.51%)

, PSTX

Poseida Therapeutics

$4.54 /

+0.125 (+2.83%)

Emerging Biotechnology…

Emerging Biotechnology Analysts Breidenbach and Biegler, along with Drs. Rossi and Braunstein, discuss the evolving treatment landscapes in multiple myeloma and non-hodgkin lymphoma on an Analyst/Industry conference call to be held on December 1 at 11 am.

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$4.54 /

+0.125 (+2.83%)

NKTX Nkarta
$8.46 /

+0.365 (+4.51%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$51.25 /

+2.64 (+5.43%)

JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

IPSC Century Therapeutics
$10.48 /

+0.14 (+1.35%)

GRCL Gracell
$3.28 /

+0.04 (+1.23%)

GILD Gilead
$87.85 /

+2.09 (+2.44%)

FATE Fate Therapeutics
$20.84 /

+1.07 (+5.41%)

DTIL Precision BioSciences
$1.36 /

+0.06 (+4.62%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

CRBU Caribou Biosciences
$9.33 /

+0.985 (+11.81%)

CLLS Cellectis
$2.22 /

+0.04 (+1.83%)

CELU Celularity
$1.71 /

+0.035 (+2.10%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

ALLO Allogene Therapeutics
$9.84 /

+0.56 (+6.03%)

ACLX Arcellx
$19.90 /

+ (+0.00%)

ACET Adicet Bio
$18.20 /

+0.42 (+2.36%)

ACET Adicet Bio
$18.20 /

+0.42 (+2.36%)

09/21/22 JPMorgan
Adicet Bio initiated with Overweight, $23 target at JPMorgan
09/21/22 JPMorgan
Adicet Bio initiated with an Overweight at JPMorgan
03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
03/17/22 JMP Securities
Adicet Bio price target lowered to $21 from $30 at JMP Securities
ACLX Arcellx
$19.90 /

+ (+0.00%)

10/31/22 Guggenheim
Arcellx initiated with a Buy at Guggenheim
10/27/22 Needham
Arcellx initiated with a Buy at Needham
07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
07/20/22 Canaccord
Arcellx initiated with a Buy at Canaccord
ALLO Allogene Therapeutics
$9.84 /

+0.56 (+6.03%)

11/21/22 H.C. Wainwright
Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
09/22/22 B. Riley
Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
09/20/22 B. Riley
B. Riley replaces Allogene with Syndax as top pick for 2022
08/10/22 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

11/17/22 Credit Suisse
Bristol-Myers initiated with a Neutral at Credit Suisse
11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
CELU Celularity
$1.71 /

+0.035 (+2.10%)

08/25/22 Alliance Global Partners
Celularity initiated with a Buy at Alliance Global Partners
08/23/22 Truist
Celularity price target lowered to $6 from $10 at Truist
06/22/22 H.C. Wainwright
Celularity initiated with a Buy at H.C. Wainwright
04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
CLLS Cellectis
$2.22 /

+0.04 (+1.83%)

08/18/22 Citi
Cellectis price target raised to $36 from $34 at Citi
05/18/22 Baird
Cellectis upgraded to Outperform at Baird on valuation 'backstop'
05/18/22 Baird
Cellectis upgraded to Outperform from Neutral at Baird
05/13/22 Barclays
Cellectis price target lowered to $7 from $9 at Barclays
CRBU Caribou Biosciences
$9.33 /

+0.985 (+11.81%)

11/23/22 Citi
Caribou Biosciences price target lowered to $37 from $38 at Citi
08/29/22 Citi
Caribou Biosciences price target lowered to $38 from $39 at Citi
08/18/22 H.C. Wainwright
Caribou Biosciences price target lowered to $27 from $28 at H.C. Wainwright
05/12/22 Citi
Caribou Biosciences price target raised to $39 from $29 at Citi
CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

11/23/22 Citi
Crispr Therapeutics price target lowered to $63 from $83 at Citi
11/02/22 Barclays
Crispr Therapeutics price target lowered to $61 from $88 at Barclays
11/02/22 Credit Suisse
Crispr Therapeutics price target lowered to $78 from $90 at Credit Suisse
10/11/22 Morgan Stanley
Crispr Therapeutics initiated with an Underweight at Morgan Stanley
DTIL Precision BioSciences
$1.36 /

+0.06 (+4.62%)

11/10/22 H.C. Wainwright
Precision BioSciences price target lowered to $17 from $20 at H.C. Wainwright
06/16/22 BMO Capital
Precision BioSciences initiated with an Outperform at BMO Capital
06/09/22 William Blair
Precision BioSciences downgraded to Market Perform at William Blair
12/13/21 BTIG
Precision BioSciences price target raised to $20 from $16 at BTIG
FATE Fate Therapeutics
$20.84 /

+1.07 (+5.41%)

11/16/22 Citi
Fate Therapeutics price target lowered to $80 from $87 at Citi
11/04/22 Cantor Fitzgerald
Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/10/22 Canaccord
Fate Therapeutics initiated with a Buy at Canaccord
08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
GILD Gilead
$87.85 /

+2.09 (+2.44%)

11/22/22 Guggenheim
MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts
11/09/22 Argus
Gilead price target raised to $100 from $70 at Argus
11/08/22 Cowen
Gilead price target raised to $90 from $80 at Cowen
11/08/22 Mizuho
Gilead price target raised to $88 from $75 at Mizuho
GRCL Gracell
$3.28 /

+0.04 (+1.23%)

09/22/22 Citi
Gracell initiated with a Buy at Citi
08/18/22 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
06/01/22 Cantor Fitzgerald
Gracell initiated with an Overweight at Cantor Fitzgerald
05/27/22 Piper Sandler
Gracell price target lowered to $10 from $25 at Piper Sandler
IPSC Century Therapeutics
$10.48 /

+0.14 (+1.35%)

11/14/22 H.C. Wainwright
Century Therapeutics price target lowered to $25 from $27 at H.C. Wainwright
11/11/22 Piper Sandler
Century Therapeutics price target raised to $24 at Piper after R&D day
10/31/22 Guggenheim
Century Therapeutics initiated with a Buy at Guggenheim
10/10/22 Canaccord
Century Therapeutics initiated with a Buy at Canaccord
JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

11/30/22 Wells Fargo
Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
11/29/22 Craig-Hallum
Craig-Hallum sees potential for competing Apollo Endosurgery bids
11/28/22 Morgan Stanley
Genmab risk/reward favorable into arbitration ruling, says Morgan Stanley
11/17/22 Credit Suisse
Johnson & Johnson initiated with a Neutral at Credit Suisse
LEGN Legend Biotech
$51.25 /

+2.64 (+5.43%)

11/01/22 Evercore ISI
Legend Biotech initiated with an Outperform at Evercore ISI
11/01/22 Cowen
Cowen starts Legend Biotech with an Outperform on Carvykti potential
11/01/22 Cowen
Legend Biotech initiated with an Outperform at Cowen
MBIO Mustang Bio
/

+

11/16/22 BTIG
Mustang Bio price target lowered to $4 from $8 at BTIG
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
07/14/22 B. Riley
Mustang Bio price target lowered to $4 from $5 at B. Riley
05/23/22 B. Riley
Mustang Bio price target lowered to $5 from $6 at B. Riley
NKTX Nkarta
$8.46 /

+0.365 (+4.51%)

11/16/22 Mizuho
Nkarta price target lowered to $26 from $81 at Mizuho
11/10/22 Oppenheimer
Nkarta price target lowered to $36 from $50 at Oppenheimer
10/10/22 Canaccord
Nkarta initiated with a Buy at Canaccord
08/12/22 Cantor Fitzgerald
Nkarta price target lowered to $38 from $60 at Cantor Fitzgerald
PSTX Poseida Therapeutics
$4.54 /

+0.125 (+2.83%)

11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
08/09/22 Piper Sandler
Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler
05/13/22 BTIG
Poseida Therapeutics price target lowered to $20 from $40 at BTIG
05/13/22 Piper Sandler
Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler
PSTX Poseida Therapeutics
$4.54 /

+0.125 (+2.83%)

NKTX Nkarta
$8.46 /

+0.365 (+4.51%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$51.25 /

+2.64 (+5.43%)

JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

IPSC Century Therapeutics
$10.48 /

+0.14 (+1.35%)

GRCL Gracell
$3.28 /

+0.04 (+1.23%)

GILD Gilead
$87.85 /

+2.09 (+2.44%)

FATE Fate Therapeutics
$20.84 /

+1.07 (+5.41%)

DTIL Precision BioSciences
$1.36 /

+0.06 (+4.62%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

CRBU Caribou Biosciences
$9.33 /

+0.985 (+11.81%)

CLLS Cellectis
$2.22 /

+0.04 (+1.83%)

CELU Celularity
$1.71 /

+0.035 (+2.10%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

ALLO Allogene Therapeutics
$9.84 /

+0.56 (+6.03%)

ACLX Arcellx
$19.90 /

+ (+0.00%)

ACET Adicet Bio
$18.20 /

+0.42 (+2.36%)

  • 04
    Aug
  • 27
    Jul
  • 17
    Jun
  • 26
    Apr
  • 04
    Feb
  • 16
    Dec
  • 08
    Dec
JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

LEGN Legend Biotech
$51.25 /

+2.64 (+5.43%)

JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

GRCL Gracell
$3.28 /

+0.04 (+1.23%)

GILD Gilead
$87.85 /

+2.09 (+2.44%)

FATE Fate Therapeutics
$20.84 /

+1.07 (+5.41%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

CRBU Caribou Biosciences
$9.33 /

+0.985 (+11.81%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

ALLO Allogene Therapeutics
$9.84 /

+0.56 (+6.03%)

ACLX Arcellx
$19.90 /

+ (+0.00%)

ACET Adicet Bio
$18.20 /

+0.42 (+2.36%)

JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

IPSC Century Therapeutics
$10.48 /

+0.14 (+1.35%)

GILD Gilead
$87.85 /

+2.09 (+2.44%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

CELU Celularity
$1.71 /

+0.035 (+2.10%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

ACLX Arcellx
$19.90 /

+ (+0.00%)

Yesterday
Hot Stocks
OncoCyte CEO Ronnie Andrews to step down, Joshua Riggs named interim CEO » 18:01
11/30/22
11/30
18:01
11/30/22
18:01
OCX

OncoCyte

/

+

Oncocyte announced that…

Oncocyte announced that Ronnie Andrews will step down from his role as CEO and as a director of the company's board of directors effective December 1. In order to ensure a smooth transition effective as of December 2, Joshua Riggs will serve as interim CEO until such time as a new CEO has been identified and retained and Andrews will continue to act a consultant until February 28, 2023. Riggs, who has been Oncocyte's General Manager, Transplant since July 2022 and was the company's Senior Director Business Development from August 2020 until September 2022, is a seasoned business development strategist with significant experience working with early and growth-stage molecular diagnostics companies. From January 2016 to July 2020, he was a principal at Bethesda Group, LLC, a boutique consulting group focused on helping small and mid-stage diagnostic companies and investment groups move emerging diagnostic content and platforms to market.

ShowHide Related Items >><<
OCX OncoCyte
/

+

OCX OncoCyte
/

+

11/17/22 Piper Sandler
OncoCyte downgraded to Neutral at Piper with revenue ramp slowing
11/17/22 Piper Sandler
OncoCyte downgraded to Neutral from Overweight at Piper Sandler
11/14/22 Piper Sandler
OncoCyte price target lowered to $1 from $1.50 at Piper Sandler
08/17/22 Piper Sandler
OncoCyte price target raised to $1.50 from $1.40 at Piper Sandler
OCX OncoCyte
/

+

  • 14
    Apr
Hot Stocks
Imago BioSciences says 1st patient dosed in bomedemstat combo study for AML » 16:19
11/30/22
11/30
16:19
11/30/22
16:19
IMGO

Imago BioSciences

$35.69 /

+0.025 (+0.07%)

Imago BioSciences…

Imago BioSciences announced that the first participant has been dosed in an investigator-sponsored Phase 1 study of bomedemstat, an investigational oral lysine-specific demethylase inhibitor, in combination with venetoclax, Venclexa in patients with relapsed or refractory acute myeloid leukemia AML. Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care The Phase 1 open-label study is being conducted at the University of Miami, led by Terrence J. Bradley, M.D. It will enroll approximately 18 adult participants diagnosed with AML who have failed at least one standard, front-line therapy and will assess the safety and efficacy of bomedemstat in combination with venetoclax , VenBom therapy,. This combination regimen consists of once daily, oral administration of both bomedemstat and venetoclax. Participants will receive three cycles of the treatment, and may continue to receive treatment as long as they experience clinical benefit or until disease progression. "This study is the first clinical study grounded on the pre-clinical work by Dr. Sheng Cai demonstrating that this combination had the potential to offer a unique benefit to patients with AML who have limited treatment options," said Hugh Young Rienhoff, Jr., M.D., Chief Executive Officer of Imago BioSciences. "We are very pleased that such an experienced team as that at the University of Miami has initiated this trial."

ShowHide Related Items >><<
IMGO Imago BioSciences
$35.69 /

+0.025 (+0.07%)

IMGO Imago BioSciences
$35.69 /

+0.025 (+0.07%)

11/28/22 Stifel
Imago BioSciences downgraded to Hold from Buy at Stifel
11/22/22 H.C. Wainwright
Imago BioSciences downgraded to Neutral from Buy at H.C. Wainwright
11/21/22 Cowen
Imago BioSciences downgraded to Market Perform from Outperform at Cowen
11/21/22 Jefferies
Imago BioSciences downgraded to Hold from Buy at Jefferies
IMGO Imago BioSciences
$35.69 /

+0.025 (+0.07%)

IMGO Imago BioSciences
$35.69 /

+0.025 (+0.07%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.